^
Association details:
Biomarker:KEAP1 negative
Cancer:Melanoma
Drug Class:PD1 inhibitor +
CTLA4 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

Published date:
03/02/2023
Excerpt:
Notably, KEAP1 expression is elevated in CTCs from CR patients and undetectable in all but one CTC from patients with PD...Thus, loss of KEAP1 expression and associated upregulation of NRF2 signaling within individual melanoma CTCs are associated with poor response to ICB in our CTC cohort.
DOI:
10.1038/s41698-023-00362-3